CLINICAL-PATOGENETIC RATIONALE FOR THE USE OF GLYCOSAMINOGLYCANS IN THE TREATMENT OF PATIENTS WITH GLOMERULONEPHRITIS. Scientific and practical journal 2023, 28 (4), 88-93. https://doi.org/10.21802/artm.2023.4.28.88.